Acumen Pharmaceuticals (ABOS) Operating Expenses (2020 - 2026)

Acumen Pharmaceuticals has disclosed Operating Expenses across 7 years of filings, most recently posting $32.6 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 22.02% year-over-year to $32.6 million; the TTM figure through Jun 2026 stood at $105.4 million (down 26.78% YoY), while the FY2025 annual figure was $123.8 million, up 8.61% from the prior year.
• Operating Expenses came in at $32.6 million for Q2 2026 at Acumen Pharmaceuticals, up from $21.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $41.8 million in Q2 2025 to a low of $9.2 million in Q1 2022.
• Average Operating Expenses over 5 years is $22.1 million, with a median of $19.8 million recorded in 2023.
• Year-over-year, Operating Expenses surged 202.56% in 2022 and plunged 36.36% in 2025.
• Over 5 years, Operating Expenses stood at $14.2 million in 2022, then climbed by 29.74% to $18.5 million in 2023, then jumped by 114.2% to $39.6 million in 2024, then slumped by 36.36% to $25.2 million in 2025, then advanced by 29.2% to $32.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $32.6 million in Q2 2026, $21.1 million in Q1 2026, and $25.2 million in Q4 2025.